Literature DB >> 9712034

Termination of peripheral tolerance to a T cell epitope by heteroclitic antigen analogues.

U Zügel1, R Wang, G Shih, A Sette, J Alexander, H M Grey.   

Abstract

Treating mice with an immunodominant T cell epitope from moth cytochrome c (MCC(88-103)) can induce T cell unresponsiveness under certain conditions of administration. In this report, we determined whether T cell tolerance to MCC(88-103) in adult animals can be overcome by immunization with cross-reactive analogues of the tolerizing Ag. A panel of analogues of the tolerogen were tested for their capacity to terminate the tolerant state following in vivo immunization. As analyzed by their stimulatory capacity for a representative MCC(88-103)-specific T cell clone, this panel covered a wide range of cross-reactivity, including nonantigenic, antagonistic, weakly, and strongly antigenic peptides. Interestingly, only heteroclitic analogues, as measured in vitro by their enhanced antigenicity for the T cell clone that was specific for MCC(88-103), were capable of breaking tolerance. Thus, an immune response to the cross-reactive, heteroclitic analogues of tolerized self Ags may represent a mechanism by which Ag molecular mimicry operates.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9712034

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

Review 1.  Manipulating antigenic ligand strength to selectively target myelin-reactive CD4+ T cells in EAE.

Authors:  Joseph J Sabatino; Kristen M Rosenthal; Brian D Evavold
Journal:  J Neuroimmune Pharmacol       Date:  2009-11-11       Impact factor: 4.147

2.  Common antigenicity between Japanese cedar (Cryptomeria japonica) pollen and Japanese cypress (Chamaecyparis obtusa) pollen, II. Determination of the cross-reacting T-cell epitope of cry j 1 and cha o 1 in mice.

Authors:  N Ohno; T Ide; M Sakaguchi; S Inouye; S Saito
Journal:  Immunology       Date:  2000-04       Impact factor: 7.397

3.  T-cell receptor-mediated anergy of a human immunodeficiency virus (HIV) gp120-specific CD4(+) cytotoxic T-cell clone, induced by a natural HIV type 1 variant peptide.

Authors:  L Bouhdoud; P Villain; A Merzouki; M Arella; C Couture
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

4.  Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy.

Authors:  L Fong; Y Hou; A Rivas; C Benike; A Yuen; G A Fisher; M M Davis; E G Engleman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-26       Impact factor: 11.205

5.  Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial.

Authors:  Nitin Jain; James M Reuben; Hagop Kantarjian; Changping Li; Hui Gao; Bang-Ning Lee; Evan N Cohen; Theresa Ebarb; David A Scheinberg; Jorge Cortes
Journal:  Cancer       Date:  2009-09-01       Impact factor: 6.860

6.  The stimulation of low-affinity, nontolerized clones by heteroclitic antigen analogues causes the breaking of tolerance established to an immunodominant T cell epitope.

Authors:  R Wang; Y Wang-Zhu; C R Gabaglia; K Kimachi; H M Grey
Journal:  J Exp Med       Date:  1999-10-04       Impact factor: 14.307

7.  Negative selection during the peripheral immune response to antigen.

Authors:  S M Anderton; C G Radu; P A Lowrey; E S Ward; D C Wraith
Journal:  J Exp Med       Date:  2001-01-01       Impact factor: 14.307

8.  Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide.

Authors:  S Tangri; G Y Ishioka; X Huang; J Sidney; S Southwood; J Fikes; A Sette
Journal:  J Exp Med       Date:  2001-09-17       Impact factor: 14.307

9.  Diversity and recognition efficiency of T cell responses to cancer.

Authors:  Tor B Stuge; Susan P Holmes; Sahdev Saharan; Andrea Tuettenberg; Mario Roederer; Jeffrey S Weber; Peter P Lee
Journal:  PLoS Med       Date:  2004-11-30       Impact factor: 11.069

10.  Improving antigenic peptide vaccines for cancer immunotherapy using a dominant tumor-specific T cell receptor.

Authors:  Jonathan D Buhrman; Kimberly R Jordan; Daniel J Munson; Brandon L Moore; John W Kappler; Jill E Slansky
Journal:  J Biol Chem       Date:  2013-10-08       Impact factor: 5.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.